Anti-PRO87299 antibodies

• US 7,479,544 B2
• Filed: 11/12/2004
• Issued: 01/20/2009
• Est. Priority Date: 10/25/2002
• Status: Active Grant

• Current Assignee: Genentech, Inc. (Roche Holding AG)
• Original Assignee: Genentech, Inc. (Roche Holding AG)
• Inventors: Gurney, Austin L., Eaton, Daniel L., Clark, Hilary, Gonzalez, Lino, Wranik, Bernd, Ouyang, Wenjun, Loyet, Kelly
• Primary Examiner(s): OUSPENSKI, ILIA I
• Application Number:
  US10/987,663
• Publication Number:
  US 20050272118A1
• Time in Patent Office: 1,530 Days
• Field of Search: None
• US Class Current: 530/387.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/02 Nasal agents, e.g. decongestants
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 : Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 5/14 : of the thyroid hormones, e.g. T3, T4
• CPC Class Codes: A61P 7/04 : Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 7/06 : Antianaemics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 14/705 : Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 16/28 : against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C07K 2319/00 : Fusion polypeptide
• CPC Class Codes: G01N 2333/705 : Assays involving receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: G01N 2800/065 : Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
• CPC Class Codes: G01N 2800/24 : Immunology or allergic disorders SLE G01N2800/104
• CPC Class Codes: G01N 2800/245 : Transplantation related diseases, e.g. graft versus host disease
• CPC Class Codes: G01N 33/5011 : for testing antineoplastic activity
• CPC Class Codes: G01N 33/57407 : Specifically defined cancers
• CPC Class Codes: G01N 33/6893 : related to diseases not provided for elsewhere

Abstract

The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related disease.

Claims

1. An isolated antibody which specifically binds to the polypeptide of SEQ ID NO:

2, wherein the antibody blocks interaction of a polypeptide comprising the amino acid sequence of SEQ ID NO;

2 or amino acids 1-155 of SEQ ID NO;

2 with the HVEM polypeptide of SEQ ID NO;

4.

2. The antibody of claim 1, wherein said antibody is a monoclonal antibody or a single-chain antibody.

4. The antibody of claim 1, which is an antibody fragment.

5. The antibody of claim 1, which is a chimeric, human, or humanized antibody.

6. An immunoconjugate comprising the antibody of claim 1 conjugated to a cytotoxic agent.

7. The antibody of claim 6, wherein the cytotoxic agent is selected from the group consisting of antibiotics, radioactive isotopes and nucleolytic enzymes.

8. The antibody of claim 6, wherein the cytotoxic agent is a toxin.

9. The antibody of claim 8, wherein the toxin is selected from the group consisting of auristatin, maytansinoid and calicheamicin.

10. The antibody of claim 8, wherein the toxin is an auristatin.

11. The antibody of claim 8, wherein the toxin is covalently attached to the antibody by a linker.

12. The antibody of claim 11, wherein the linker is selected from the group consisting of maleimidocaproyl (MC), valine-citrulline (val-cit, vc), citrulline (2-amino-5ureido pentanoic acid), PAB (p-aminobenzylcarbamoyl), Me (N-methyl-valine citrulline), MC(PEG)6-OH (maleimidocaproyl-polyethylene glycol), SPP (N-Succinimidyl 4-(2-pyridylthio) pentanoate), SMCC (N-Succinimidyl 4-(N-maleimidomethyl) cyclohexane-1 carboxylate), and MC-vc-PAB.

13. The antibody of claim 1, which is produced in bacteria.

14. The antibody of claim 1 which is produced in CHO cells.

15. A composition comprising the antibody of claim 1 conjugated to a detectable label.

16. A composition of matter comprising the isolated antibody of claim 1 in combination with a pharmaceutically acceptable carrier.

17. The isolated antibody of claim 1, wherein the isolated antibody specifically binds to amino acids 1-155 of SEQ ID NO:

2.

18. A method of blocking interaction of (a) a polypeptide comprising the extracellular domain of SEQ ID NO:

4 with (b) a polypeptide comprising the extracellular domain of SEQ ID NO;

2, the method comprising exposing a mixture comprising (a) and (b) to the antibody of claim 1.

3. An isolated antibody produced by the hybridoma Btig5F5.1 (ATCC Accession No. PTA-6302) or hybridoma Btig3B1.9 (ATCC Accession No. PTA-6301).